Alzheimer’s Drug Market, By Drug (Donepezil, Memantine, Galantamine, Rivastigmine, Donanemab and Gantenerumab), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and E-Commerce), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

The market for Alzheimer's drugs was valued at US$ 3.79 billion in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% to reach US$ 8.86 billion by 2030.

One of the most prevalent neurodegenerative disorders, Alzheimer's disease has been associated with increased life expectancies globally. A primary sign of dementia is a range of behavioral abnormalities that get worse as the illness advances. Individuals over 65 are the main target audience. Although there isn't a pharmaceutical treatment for Alzheimer's disease at the moment, several drugs can assist lessen the illness's symptoms and severity. Many companies have invested in the development of new drugs to treat Alzheimer's disease, but only a small number of molecules have consistently improved patient condition, and during phase three clinical trials, many of those investigational candidates failed to show a discernible improvement in patient condition.